Document is current
Any future updates will be listed below
-
Authors
Köhnke, Thomas
Liu, Xilong
Haubner, Sascha
Bücklein, Veit
Hänel, Gerulf
Krupka, Christina
Solis-Mezarino, Victor
Herzog, Franz
Subklewe, Marion
-
Funding
Funding for this research was provided by:
Friedrich-Baur-Stiftung
China Scholarship Council (201307040012)
Else Kröner-Fresenius-Stiftung
Wilhelm Sander-Stiftung (2018.087.1, 2018.087.1)
Deutsche Forschungsgemeinschaft (Quantitative Biosciences Munich, SFB 1243 project A10)
European Research Council (638218)
Human Frontier Science Program (RGP0008/2015)
Bavarian Elite Graduate School “i-target”
Universitätsklinik München
- License Information
-
More Information
Article History
Received: 3 March 2022
Accepted: 1 June 2022
First Online: 10 June 2022
Declarations
:
: Patient specimens used in this study were obtained after informed consent in accordance with the Declaration of Helsinki and approval by the Institutional Review Board of the Ludwig-Maximilians-Universität (Munich, Germany).
: Not applicable.
: M.S. has received research support from Amgen, Gilead, Miltenyi Biotec, Morphosys, Roche, and Seattle Genetics, sits on the advisory boards of Amgen, Celgene, Gilead, Janssen, Novartis, Pfizer, and Seattle Genetics, serves on the speakers' bureau at Amgen, Celgene, Gilead, Janssen, and Pfizer, and has served as a consultant/advisor to Amgen, BMS, Celgene, Gilead, Pfizer, Novartis, and Roche.
